ESPR Stock Analysis: Buy, Sell, or Hold?
ESPR - Esperion Therapeutics, Inc.
$3.13
0.00 (0.00%)
▲
5d:
+0.32%
30d:
+63.02%
90d:
-11.08%
BUY
MODERATE Confidence
Analysis Updated: May 20, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When ESPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ESPR this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ESPR shows positive signals but monitor for confirmation. Market pricing in 38.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ESPR shows positive signals but monitor for confirmation. Market pricing in 38.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.23
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.35
50.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ESPR is currently trading at $3.13, which is considered slightly high relative to its 30-day fair value range of $2.00 to $3.13. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.7) compared to its historical average (46.9). Remarkably, the market is currently pricing in an annual earnings decline of 38.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ESPR is in a strong uptrend. The price is currently testing key support at $3.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ESPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ESPR is in a strong uptrend. The price is currently testing key support at $3.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ESPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.00 -
$3.13
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
71.4%
Protect Your Profits
ESPR is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($3.19)
Trading Range Analysis
30-Day Trading Range
$2.00 -
$3.13
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.11
Resistance Level
$3.15
Current Trend
Strong Uptrend
Technical data as of
May 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.72
Wall Street Target
$3.19
(+1.9%)
Revenue Growth (YoY)
23.2%
Profit Margin
-1.8%
Valuation Discount vs History
-38.8% cheaper
PE vs Historical
10.7 vs 46.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-38.8%
(market-implied from PE analysis)
1-Year Target
$2.82
(-10%)
2-Year Target
$2.54
(-19%)
3-Year Target
$2.28
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→47)
$9.98
(+219%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.7 to 46.9
Stabilization Target:
$13.69
(+337.5%)
PE Expansion Potential:
+337.5%
Share & Embed Analysis
Last updated: May 20, 2026 11:14 PM ET
Data refreshes hourly during market hours. Next update: 12:14 AM
Data refreshes hourly during market hours. Next update: 12:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ESPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Halladay
SELL
6424 shares
2026-03-17
Benjamin Looker
SELL
5708 shares
2026-03-17
Benjamin Looker
SELL
1689 shares
2026-01-20
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 60 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 54 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced ESPR Option Strategies
Professional options setups generated by AI based on today's ESPR price and gamma walls.
